by susan.forootan | Nov 10, 2023
Coinciding with the 2023 Society for Neuroscience meeting, the company rolls out a new logo and tagline, website, and booth (#2201). PARAMUS, NJ, November 10, 2023 — PsychoGenics, Inc. (“PsychoGenics” or the “Company”), the leading contract research organization (CRO)...
by Kelly Morris | Sep 5, 2023
September 5, 2023, Paramus, New Jersey – PsychoGenics Inc. (PsychoGenics) and Collaborations Pharmaceuticals, Inc. (CPI) are pleased to announce that they were awarded a $1million Phase I Small Business Innovation Research (SBIR) grant, to use their combined AI...
by marcbacon | Oct 11, 2022
PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that clinical-stage biopharmaceutical company Karuna Therapeutics, Inc., (NASDAQ: KRTX)...
by marcbacon | Jun 29, 2022
Biopharmaceutical Industry Veterans David Bleakman and Thomas Oakley Each Bring Three Decades of Experience to the Company Paramus, N.J., June 28, 2022 – PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery...
by marcbacon | Jan 25, 2022
PsychoGenics Inc. (PGI), a provider of AI-based phenotypic platforms and preclinical assays for the development of therapeutics for pain, neurodegenerative, psychiatric, and developmental disorders, announced that the National Institutes of Health (NIH) has completed...
